Article

A MALDI-TOF assay identifies nilotinib as an inhibitor of inflammation in acute myeloid leukaemia

2021-03-30

Abstract excerpt

<h4>ABSTRACT</h4> Inflammatory responses are important in cancer, particularly in the context of monocyte-rich aggressive myeloid neoplasm. We developed a label-free cellular phenotypic drug discovery assay to identify anti-inflammatory drugs in human monocytes derived from acute myeloid leukaemia (AML), by tracking several biological features ionizing from only 2,500 cells using matrix-assisted laser desorption/...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 30f6b5bd-59d1-5dbc-9c37-9e23a0241541
DOI: 10.1101/2021.03.29.437557

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A MALDI-TOF assay identifies nilotinib as an inhibitor of inflammation in acute myeloid leukaemiaDOI 10.1101/2021.03.29.437557Read

The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells.Semantic proximity Read

Autophagy inhibitors block pathogenic NET release in immune-mediated inflammatory disease without impairing host defenceSemantic proximity Read

MALDI-TOF mass spectrometry and proteomics as phenotypic screening tools for anti-inflammatory drugsSemantic proximity Read

Inference of kinase-signaling networks in human myeloid cell line models by Phosphoproteomics using kinase activity enrichment analysis (KAEA).Semantic proximity Read

Identification of Common Genes and Pathways Underlying Imatinib and Nilotinib Treatment in CML: a Bioinformatics StudySemantic proximity Read

Imatinib and Nilotinib Off-Target Effects on Human NK Cells, Monocytes, and M2 MacrophagesSemantic proximity Read

Protein neddylation governs the inflammatory status of healthy and malignant myeloid cells in response to TLR stimulationSemantic proximity Read

Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T-cell phenotype.Semantic proximity Read

Pathogen and human NDPK-proteins promote AML cell survival via monocyte NLRP3-inflammasome activationSemantic proximity Read

Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia.Semantic proximity Read

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.Semantic proximity Read

Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically EquivalentSemantic proximity Read